The role of the polyol pathway in diabetes mellitus.
The mechanism by which hyperglycaemia leads to diabetic complications has not been fully elucidated. Non-enzymatic glycosylation leads to considerable functional and structural alteration of proteins. Hyperglycaemia also induces changes in intracellular metabolites, particularly in the polyol pathway. Aldose reductase inhibitors, which block the polyol pathway, have been shown to prevent complications in animal models, and this provides the rationale for the large scale trials that are presently being conducted.
Collier
A
A
Gartnaval General Hospital, Glasgow.
Small
M
M
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000502:physiology; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy; D006019:Glycolysis; D006031:Glycosylation; D006801:Humans; D006943:Hyperglycemia / Q000097:blood* / Q000201:enzymology / Q000209:etiology; D007093:Imidazoles / Q000627:therapeutic use; D048289:Imidazolidines; D009281:Naphthalenes / Q000627:therapeutic use; D010793:Phthalazines / Q000627:therapeutic use; D012236:Rhodanine / Q000031:analogs & derivatives; D053778:Thiazolidines
D007093:Imidazoles; D048289:Imidazolidines; D009281:Naphthalenes; D010793:Phthalazines; D053778:Thiazolidines; C040550:tolrestat; C042829:ponalrestat; C038131:epalrestat; D012236:Rhodanine; D000449:Aldehyde Reductase; C026411:sorbinil